Rab7 GTPase Inhibitors for Hereditary Neuropathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rab7 GTPase-associated disorders, such as hereditary sensory neuropathies and cancer, lack specific small molecule inhibitors, relying on non-specific prenylation strategies and lacking nucleotide binding inhibitors, which are ineffective and have adverse side effects.
Innovation Solution
Development of small molecule inhibitors, like CID1067700, that target the nucleotide binding site of Rab7 GTPase, offering selective modulation of Rab7 activity to treat or prevent associated disorders by administering compounds that bind to the GTP or GDP-bound conformations, thereby activating or inactivating Rab7 function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific prenylation strategies are used to inhibit Ras and Ras-related proteins, then inhibition of protein function is achieved, but specificity is lost and adverse side effects occur
Solution Approach 1:
The invention segments the broad prenylation pathway into specific targets by developing compounds that selectively inhibit Rab7 GTPase prenylation while sparing other Rab proteins and prenylation pathways. This is achieved through structure-activity relationship optimization that confers selectivity for Rab7 over other prenylated proteins, thereby maintaining inhibition effectiveness while reducing adverse side effects associated with non-specific prenymlation inhibition
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific molecular characteristics that target the prenylation site of Rab7 GTPase specifically. The compounds possess structural features (such as specific functional groups and spatial arrangements) that enable selective binding to Rab7 prenylation machinery, creating localized inhibition at the Rab7 prenymlation site while leaving other prenymlation processes unaffected, thus reducing systemic adverse effects
2Object-affected harmful factors
If selective Rab7 inhibitors are developed, then specificity and reduced side effects are achieved, but such inhibitors did not previously exist
Solution Approach 1:
The invention performs preliminary action by conducting extensive structure-activity relationship studies and high-throughput screening to identify and optimize lead compounds with selective Rab7 inhibitory activity before clinical application. This preliminary optimization phase established the structural requirements for Rab7 selectivity, creating a foundation of prevalidated selective inhibitors that can be directly applied to treat Rab7-associated disorders without the need for further extensive screening
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters (such as substituent groups, molecular weight, lipophilicity) of inhibitor candidates to optimize selectivity for Rab7. By adjusting these chemical parameters, the invention transforms non-selective prenymlation inhibitors into Rab7-selective compounds, thereby expanding the availability of adaptable selective inhibitors for Rab7-associated diseases
Data Source
AI summary
This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.